



SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 20 88 60 94

Classification of the application (IPC):
A61K 31/42, A61K 31/4545, C07D 261/08, C07D 413/12

Technical fields searched (IPC):
A61K, A61P

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
X	WO 2019023245 A1 (CEDARS SINAI MEDICAL CENTER [US]) 31 January 2019 (2019-01-31) * paragraphs [0065] - [0068]; claims *	1-16
X	KLUCHER KEVIN ET AL: "FRI-313-A novel farnesoid X receptor agonist, TERN-101, reduces liver steatosis, inflammation, ballooning and fibrosis in a murine model of non-alcoholic steatohepatitis" <i>JOURNAL OF HEPATOLOGY</i> AMSTERDAM, NL 01 April 2019 (2019-04-01), vol. 70, no. 1, DOI: 10.1016/S0618-8278(19)31056-4, ISSN: 0168-8278, page e534, XP093103535 * the whole document *	1-16
X	Anonymous: "Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist TERN-101 at The Liver Meeting 2019 Business Wire", 15 October 2019 (2019-10-15), pages 1-2 URL: https://www.businesswire.com/news/home/20191015005032/en/Terns-Pharmaceuticals-to-Present-Positive-Preclinical-Data-on-FXR-Agonist-TERN-101-at-The-Liver-Meeting-2019 [retrieved on 20 November 2023 (2023-11-20)] XP093103551 * the whole document *	1-16
X	Gege Christian ET AL: "Nonsteroidal FXR Ligands: Current Status and Clinical Applications" In: "Bile Acids and Their Receptors", ChamSpringer International Publishing, 14 June 2019 (2019-06-14) vol. 256, pages 167-205, ISBN: 978-3-030-22005-1, XP093103470 * page 188 - page 195 *	1-16

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search Munich	Date of completion of the search 01 December 2023	Examiner Büttner, Ulf
---------------------------	--	--------------------------

CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone	P: intermediate document
Y: particularly relevant if combined with another document of the same category	T: theory or principle underlying the invention
A: technological background	E: earlier patent document, but published on, or after the filing date
O: non-written disclosure	D: document cited in the application
& : member of the same patent family, corresponding document	L: document cited for other reasons

Disclaimer: this document has been automatically generated using data structured in accordance with WIPO standard ST.36 from the database of search reports of the European Patent Office. For technical reasons, its content and layout may differ from that of the original publication. Only the original published information is legally binding.



SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 20 88 60 94

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
A	<p>GENIN MICHAEL J. ET AL: "Discovery of 6-(4-{{5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl}methoxy}piperidin-1-yl)-1-methyl-1 H -indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia" <i>JOURNAL OF MEDICINAL CHEMISTRY</i> US 14 November 2015 (2015-11-14), vol. 58, no. 24, DOI: 10.1021/acs.jmedchem.5b01161, ISSN: 0022-2623, pages 9768-9772, XP055932709 * page 9770, last paragraph * * page 9771, last paragraph *</p>	1-16
A	<p>CARR ROTONYA M ET AL: "FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease" <i>CURRENT ATHEROSCLEROSIS REPORTS, SPRINGER US, NEW YORK</i>, 18 February 2015 (2015-02-18), vol. 17, no. 4, DOI: 10.1007/S11883-015-0500-2, ISSN: 1523-3804, pages 1-14, XP035470130 * page 16, last paragraph *</p>	1-16
A	<p>YUJIN WANG ET AL: "Pharmacokinetics, Tissue Distribution and Pharmacodynamics of TERN-101, a Novel Farnesoid Xreceptor (FXR) Agonist, in Preclinical Species" <i>HEPATOLOGY; AASLD ABSTRACTS, JOHN WILEY & SONS, INC, US</i>, 01 October 2019 (2019-10-01), vol. 70, no. Suppl. 1, ISSN: 0270-9139, page 1277, XP009550030 * the whole document *</p>	1-16

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search Munich	Date of completion of the search 01 December 2023	Examiner Büttner, Ulf
---------------------------	--	--------------------------

CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone	P: intermediate document
Y: particularly relevant if combined with another document of the same category	T: theory or principle underlying the invention
A: technological background	E: earlier patent document, but published on, or after the filing date
O: non-written disclosure	D: document cited in the application
& : member of the same patent family, corresponding document	L: document cited for other reasons

Disclaimer: this document has been automatically generated using data structured in accordance with WIPO standard ST.36 from the database of search reports of the European Patent Office. For technical reasons, its content and layout may differ from that of the original publication. Only the original published information is legally binding.



ANNEX TO SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 20 88 60 94

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on 01-12-2023
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO2019023245	A1	31-01-2019	EP	3658139 A1	03-06-2020
			US	2021121493 A1	29-04-2021
			WO	2019023245 A1	31-01-2019